Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ramipril

FDA-approved product (capsule, oral), marketed as Altace, Ramipril, Vostally.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ramipril
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myocardial infarction
  • Cardiovascular disease
  • Congestive heart failure
  • Coronary artery disease
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
FDA pharmacologic class
Angiotensin Converting Enzyme Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ramipril in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ramipril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

    NCT07259512 · start 2025-06-30

    Registered record
    Registry ID
    NCT07259512
    Conditions
    Chronic Kidney Disease; Heart Failure With Reduced Ejection Fraction (HFrEF)
    Interventions
    Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-06-30
    Completion
    2026-01-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Heart Failure With Reduced Ejection Fraction (HFrEF)
    InterventionRamipril
    PhasePhase 4
    Registry statusRecruiting

  • Treatment of Patients With Diabetic Kidney Disease

    NCT06187493 · start 2024-01-01

    Registered record
    Registry ID
    NCT06187493
    Conditions
    Diabetic Kidney Disease
    Interventions
    lisinopril, enalapril; dapagliflozin, empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    Interventionlisinopril, enalapril; dapagliflozin, empagliflozin
    PhaseNot applicable
    Registry statusUnknown

  • Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

    NCT06104423 · start 2023-10-02

    Registered record
    Registry ID
    NCT06104423
    Conditions
    Hypertension
    Interventions
    Nebivolol 5 mg; Ramipril 2.5/5/10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-10-02
    Completion
    2024-02-19
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionNebivolol 5 mg; Ramipril 2.5/5/10 mg
    PhasePhase 4
    Registry statusCompleted

  • Role of Coenzyme Q10 in Chronic Kidney Disease

    NCT05942027 · start 2023-07-15

    Registered record
    Registry ID
    NCT05942027
    Conditions
    Chronic Kidney Diseases
    Interventions
    Placebo; Co-Enzyme Q10
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-07-15
    Completion
    2026-07-15
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases
    InterventionPlacebo; Co-Enzyme Q10
    PhasePhase 4
    Registry statusRecruiting

  • The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction

    NCT05508035 · start 2023-07-13

    Registered record
    Registry ID
    NCT05508035
    Conditions
    Heart Failure With Moderately Reduced Ejection Fraction
    Interventions
    Sacubitril / Valsartan; Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-07-13
    Completion
    2028-12
    Enrolment
    488

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Moderately Reduced Ejection Fraction
    InterventionSacubitril / Valsartan; Ramipril
    PhasePhase 3
    Registry statusRecruiting

  • Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions

    NCT05685277 · start 2022-12-28

    Registered record
    Registry ID
    NCT05685277
    Conditions
    Bioequivalence
    Interventions
    Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg; Tritace® Plus tablet 10 mg/25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-12-28
    Completion
    2023-07-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionRamipril/Hydrochlorothiazide tablet 10 mg/25 mg; Tritace® Plus tablet 10 mg/25 mg
    PhasePhase 1
    Registry statusCompleted

  • Cross-over Study of Coronary Risk Factors With a Polypill

    NCT05030818 · start 2022-10-14

    Registered record
    Registry ID
    NCT05030818
    Conditions
    Coronary Artery Disease
    Interventions
    Polypill of acetylsalicylic acid, ramipril and atorvastatin; Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-10-14
    Completion
    2026-04-30
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPolypill of acetylsalicylic acid, ramipril and atorvastatin; Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination

    NCT04143412 · start 2019-02-04

    Registered record
    Registry ID
    NCT04143412
    Conditions
    Diabetic Nephropathy Type 2; Microalbuminuria Due to Type 2 Diabetes Mellitus
    Interventions
    Tritace (Ramipril 10 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-02-04
    Completion
    2020-03
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy Type 2; Microalbuminuria Due to Type 2 Diabetes Mellitus
    InterventionTritace (Ramipril 10 mg)
    PhasePhase 2
    Registry statusUnknown

  • Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

    NCT02200822 · start 2014-07

    Registered record
    Registry ID
    NCT02200822
    Conditions
    Heart Failure (HF)
    Interventions
    beta blockers; RAAS blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    Interventionbeta blockers; RAAS blockers
    PhasePhase 4
    Registry statusCompleted

  • Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

    NCT02008786 · start 2014-06

    Registered record
    Registry ID
    NCT02008786
    Conditions
    Coronary Artery Dissection, Spontaneous
    Interventions
    ramipril; rosuvastatin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-06
    Completion
    2019-09-13
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Dissection, Spontaneous
    Interventionramipril; rosuvastatin; placebo
    PhasePhase 4
    Registry statusTerminated

  • Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes

    NCT02086019 · start 2014-05-01

    Registered record
    Registry ID
    NCT02086019
    Conditions
    Acute Coronary Syndromes
    Interventions
    Conservative Arm; Invasive Arm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05-01
    Completion
    2019-12-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndromes
    InterventionConservative Arm; Invasive Arm
    PhaseNot applicable
    Registry statusCompleted

  • Multi-cap for Increase Adherence After Acute Myocardial Infarction

    NCT02271178 · start 2014-04

    Registered record
    Registry ID
    NCT02271178
    Conditions
    Myocardial Infarction
    Interventions
    Combined capsule; Conventional therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-04
    Completion
    2016-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    InterventionCombined capsule; Conventional therapy
    PhasePhase 3
    Registry statusTerminated

  • Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

    NCT03011775 · start 2012-11

    Registered record
    Registry ID
    NCT03011775
    Conditions
    Adverse Effect; Atherosclerosis, Coronary; Insulin Resistance Syndrome
    Interventions
    Pioglitazone 15 mg Tablet; Isosorbide Dinitrate 10Mg Tablet; Acetylsalicylic Acid 75Mg Tablet; Bisoprolol Fumarate 2.5 MG Oral Tablet; Rosuvastatin Calcium 20 MG Oral Tablet; Ramipril 5 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2015-09
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effect; Atherosclerosis, Coronary; Insulin Resistance Syndrome
    InterventionPioglitazone 15 mg Tablet; Isosorbide Dinitrate 10Mg Tablet; Acetylsalicylic Acid 75Mg Tablet; Bisoprolol Fumarate 2.5 MG Oral Tablet +2 more
    PhasePhase 4
    Registry statusCompleted

  • Cardiac Energetics and Function in Normal Human Ageing

    NCT01504828 · start 2012-07

    Registered record
    Registry ID
    NCT01504828
    Conditions
    Left Ventricular Function Systolic Dysfunction; Left Ventricular Function Diastolic Dysfunction; Ageing
    Interventions
    Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-12
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeft Ventricular Function Systolic Dysfunction; Left Ventricular Function Diastolic Dysfunction; Ageing
    InterventionRamipril
    PhaseNot applicable
    Registry statusCompleted

  • Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy

    NCT01743014 · start 2012-07

    Registered record
    Registry ID
    NCT01743014
    Conditions
    Diabetes Type 2; Diabetic Nephropathy; Vascular Disease
    Interventions
    Ramipril; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-07
    Completion
    2015-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Type 2; Diabetic Nephropathy; Vascular Disease
    InterventionRamipril; Clopidogrel
    PhasePhase 4
    Registry statusUnknown